



ISSN: 2347-6567

International Journal of Allied Medical Sciences and Clinical Research (IJAMSCR)

IJAMSCR | Vol.14 | Issue 2 | Apr - Jun - 2026

www.ijamscr.com

DOI : <https://doi.org/10.61096/ijamscr.v14.iss2.2026.1112-1116>

Impact of FODMAPs on Gut Health and Irritable Bowel Syndrome: A Comprehensive Review

Chalavadi Sudha Bhargavi^{1*}, Duddagi Suchitra², Narender Boggula³

^{1*} PhD Research Scholar, Department of Pharmacology, Sri Balaji Vidyapeeth, Deemed to be University, Pillayarkuppam, Puducherry-607403, India.

² Associate Professor, Head Department of Pharmaceutical Analysis and Quality Assurance, Vision College of Pharmaceutical Sciences and Research, Boduppal, Hyderabad-500092, Telangana, India.

³ Associate Professor, Head Department of Pharmaceutical Chemistry, Omega College of Pharmacy, Edulabad, Ghatkesar, Hyderabad-501301, India.

Corresponding Author: **Chalavadi Sudha Bhargavi***

Email: sudhabhargavichalavadi@gmail.com



Published on:
24.06.2026
Published by:
Futuristic
Publications
2026| All rights
reserved.



Creative Commons
Attribution 4.0
International
License.

Abstract: Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. Dietary factors play a crucial role in symptom exacerbation and management. Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAPs) are short-chain carbohydrates that are poorly absorbed in the small intestine and rapidly fermented by colonic bacteria. These properties contribute to increased luminal water content, gas production, and gastrointestinal symptoms in susceptible individuals. Over the last decade, the low-FODMAP diet has emerged as an effective dietary intervention for IBS management. This review discusses the classification of FODMAPs, their effects on gut physiology and microbiota, mechanisms underlying symptom generation, clinical evidence supporting low-FODMAP diets, and future research perspectives. Current evidence indicates that low-FODMAP diets significantly improve IBS symptoms and quality of life; however, long-term dietary restriction requires careful monitoring to avoid adverse effects on gut microbiota and nutritional status.

Keywords: FODMAPs, Irritable Bowel Syndrome, Gut Health, Low-FODMAP Diet, Gut Microbiota, Gastrointestinal Disorders

1. Introduction

Irritable Bowel Syndrome (IBS) is one of the most common functional gastrointestinal disorders, affecting approximately 10–15% of the global population [1, 2]. The disorder is characterized by recurrent abdominal pain associated with altered bowel habits, including diarrhea, constipation, or mixed bowel patterns [3]. Although IBS is not associated with structural abnormalities, it significantly affects patients' quality of life and imposes substantial healthcare costs worldwide [4]. The pathophysiology of IBS is multifactorial and includes abnormalities in gut motility, visceral hypersensitivity, altered intestinal permeability, immune activation, dysbiosis of gut microbiota, and disturbances in the gut-brain axis [3, 4]. Among these factors, diet has gained increasing attention because many patients report worsening of symptoms following food intake [5]. Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAPs) represent a group of short-chain carbohydrates that are poorly absorbed in the small intestine [6]. These carbohydrates exert osmotic effects and undergo rapid fermentation by colonic bacteria, resulting in luminal distension and gastrointestinal discomfort [7]. The concept of FODMAP restriction was introduced by Gibson and Shepherd and has since become a cornerstone in dietary management of IBS [6]. This review

aims to summarize current knowledge regarding the impact of FODMAPs on gut health and IBS, focusing on mechanisms of action, clinical evidence, benefits, limitations, and future therapeutic perspectives.

2. FODMAPs: Definition and Classification

FODMAPs comprise a diverse group of fermentable carbohydrates that are either poorly absorbed or not absorbed in the human small intestine [6].

Table 1: Classification of FODMAPs and Common Food Sources

FODMAP Category	Examples	Food Sources
Oligosaccharides	Fructans, Galacto-oligosaccharides	Wheat, onion, garlic, legumes
Disaccharides	Lactose	Milk, yogurt, soft cheese
Monosaccharides	Excess Fructose	Apples, pears, mangoes, honey
Polyols	Sorbitol, Mannitol, Xylitol	Stone fruits, mushrooms, artificial sweeteners

These compounds are osmotically active and rapidly fermented by gut microbiota, leading to gastrointestinal symptoms in susceptible individuals [7].

3. Pathophysiology of IBS

The development of IBS involves multiple interconnected mechanisms:

3.1 Visceral Hypersensitivity

Patients with IBS exhibit heightened sensitivity to intestinal distension, resulting in abdominal pain and discomfort at lower thresholds than healthy individuals [8].

3.2 Altered Gastrointestinal Motility

Abnormal gut motility contributes to constipation, diarrhea, and irregular bowel movements observed in IBS patients [9].

3.3 Gut Microbiota Dysbiosis

Changes in the composition and function of intestinal microbiota have been implicated in IBS pathogenesis [10]. Reduced microbial diversity and altered bacterial populations may contribute to symptom severity.

3.4 Gut-Brain Axis Dysfunction

Bidirectional communication between the gastrointestinal tract and central nervous system influences gastrointestinal sensation, motility, and immune responses [11].

3.5 Immune Activation and Intestinal Permeability

Low-grade inflammation and increased intestinal permeability may promote symptom generation and disease progression [12].

4. Mechanisms by Which FODMAPs Affect Gut Health

4.1 Osmotic Activity

FODMAPs increase water content in the intestinal lumen because they are poorly absorbed in the small intestine. This increase in luminal water can accelerate intestinal transit and contribute to diarrhea and abdominal discomfort [13].

4.2 Fermentation and Gas Production

Once FODMAPs reach the colon, they are rapidly fermented by resident bacteria, producing hydrogen, methane, and carbon dioxide gases [14]. Excessive gas production leads to bloating, abdominal distension, and pain, particularly in individuals with visceral hypersensitivity.

4.3 Effects on Gut Microbiota

Certain FODMAPs possess prebiotic properties and stimulate the growth of beneficial microorganisms such as Bifidobacteria and Lactobacilli [15]. While short-term restriction improves symptoms, prolonged elimination may negatively affect microbial diversity [16].

4.4 Effects on Intestinal Barrier Function

Emerging evidence suggests that fermentation products derived from FODMAP metabolism may influence intestinal barrier integrity and immune responses [17].

5. Low-FODMAP Diet as a Therapeutic Strategy

The low-FODMAP diet is implemented in three phases:

Phase 1: Restriction

High-FODMAP foods are eliminated for 2–6 weeks to reduce symptom burden.

Phase 2: Reintroduction

Individual FODMAP groups are systematically reintroduced to identify specific triggers.

Phase 3: Personalization

A tailored long-term dietary plan is developed based on patient tolerance.

Numerous studies have demonstrated significant improvements in abdominal pain, bloating, stool consistency, and quality of life following implementation of a low-FODMAP diet [18].

6. Clinical Evidence Supporting Low-FODMAP Diets

Table 2: Summary of Clinical Studies Investigating FODMAPs and IBS

Author (Year)	Study Design	Sample Size	Major Findings
Gibson & Shepherd (2010)	Review	-	Introduced FODMAP concept
Halmos et al. (2014)	Randomized Crossover Trial	30	Significant reduction in GI symptoms
Staudacher et al. (2012)	Controlled Trial	41	Reduced bloating and abdominal pain
Böhn et al. (2015)	RCT	75	Improved IBS symptom severity
Eswaran et al. (2016)	RCT	92	Improved quality of life
Marsh et al. (2016)	Meta-analysis	Multiple studies	Confirmed efficacy of low-FODMAP diet
McIntosh et al. (2017)	Clinical Study	IBS patients	Altered microbiota composition
Varjú et al. (2017)	Meta-analysis	397	Reduced abdominal pain and bloating
O'Keeffe et al. (2018)	Prospective Study	IBS patients	Improved symptom control
Whelan et al. (2018)	Systematic Review	Multiple studies	Strong evidence for symptom relief
Bellini et al. (2020)	Review	IBS patients	Effective dietary strategy
Van Lanen et al. (2021)	Systematic Review	Multiple studies	Superior efficacy compared to standard dietary advice
Black and Ford (2022)	Review	IBS patients	Recommended dietary intervention

7. Benefits of Low-FODMAP Diet

The low-FODMAP diet offers several advantages:

- Significant reduction in abdominal pain
- Improvement in bloating and flatulence
- Better stool consistency
- Enhanced quality of life
- Reduced symptom severity scores
- Non-pharmacological management approach

Studies indicate that approximately 50–80% of IBS patients experience symptom improvement following dietary intervention [19-22].

8. Limitations and Challenges

- Despite its effectiveness, the low-FODMAP diet presents several challenges:
- Risk of nutritional deficiencies during prolonged restriction
- Reduced intake of beneficial prebiotic fibers
- Potential reduction in beneficial gut bacteria
- Complexity of dietary implementation
- Requirement for dietitian supervision

Therefore, long-term adherence should involve careful monitoring and gradual food reintroduction [23-28].

9. Future Perspectives

Future research should focus on:

- Personalized nutrition based on microbiome profiling.
- Biomarkers predicting responsiveness to low-FODMAP diets.
- Long-term safety studies.
- Combination therapies involving probiotics, prebiotics, and dietary interventions.
- Development of precision dietary approaches for IBS subtypes.

Advances in microbiome research may help identify patients most likely to benefit from FODMAP restriction while minimizing adverse effects on gut microbial diversity.

10. Conclusion

FODMAPs play a significant role in the pathogenesis and symptom generation of IBS through osmotic effects, gas production, and modulation of gut microbiota. Clinical evidence strongly supports the use of low-FODMAP diets as an effective therapeutic strategy for symptom management. While short-term benefits are well established, long-term dietary restriction requires careful monitoring to maintain nutritional adequacy and microbial health. Future personalized dietary approaches may further optimize IBS treatment and improve patient outcomes.

References

1. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014; 6:71-80.
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin Epidemiol. 2012; 4:71-80.
3. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: A clinical review. JAMA. 2015; 313(9):949-958.
4. Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med. 2017; 376(26):2566-2578.
5. Simrén M, Månsson A, Langkilde AM, Svedlund J, Abrahamsson H, Bengtsson U, Björnsson ES. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion. 2001; 63(2):108-115.
6. Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. J Gastroenterol Hepatol. 2010; 25(2):252-258.
7. Barrett JS. Extending our knowledge of fermentable short-chain carbohydrates for managing gastrointestinal symptoms. J Gastroenterol Hepatol. 2013; 28(Suppl 4):42-46.
8. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 1995; 109(1):40-52.

9. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. *Gastroenterology*. 2012; 142(6):1140-1149.
10. Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, Moayyedi P. Gut microbiota in patients with irritable bowel syndrome: A systematic review. *Gastroenterology*. 2019; 157(1):97-108.
11. Mayer EA. Gut feelings: The emerging biology of gut-brain communication. *Nat Rev Gastroenterol Hepatol*. 2011; 8(10):523-531.
12. Ohman L, Simrén M. Pathogenesis of IBS: Role of inflammation, immunity and neuroimmune interactions. *Nat Rev Gastroenterol Hepatol*. 2010; 7(3):163-173.
13. Shepherd SJ, Gibson PR. Fructose malabsorption and symptoms of irritable bowel syndrome. *J Am Diet Assoc*. 2006; 106(10):1631-1639.
14. Ong DK, Mitchell SB, Barrett JS, Shepherd SJ, Irving PM, Biesiekierski JR, Smith S, Gibson PR. Manipulation of dietary short-chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. *J Gastroenterol Hepatol*. 2010; 25(8):1366-1373.
15. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Reid G. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the definition and scope of prebiotics. *Nat Rev Gastroenterol Hepatol*. 2017; 14(8):491-502.
16. McIntosh K, Reed DE, Schneider T, Dang F, Keshteli AH, De Palma G, Madsen K, Bercik P, Vanner S. FODMAPs alter symptoms and the metabolome of patients with irritable bowel syndrome. *Gut*. 2017; 66(7):1241-1251.
17. Valeur J, Småstuen MC, Knudsen T, Lied GA, Roseth AG. Exploring relationships between gut microbiota and intestinal permeability in irritable bowel syndrome. *Scand J Gastroenterol*. 2018; 53(2):123-130.
18. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. *Gastroenterology*. 2014; 146(1):67-75.
19. Staudacher HM, Lomer MCE, Anderson JL, Barrett JS, Muir JG, Irving PM, Whelan K. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. *J Nutr*. 2012; 142(8):1510-1518.
20. Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H, Simrén M. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome. *Gastroenterology*. 2015; 149(6):1399-1407.
21. Eswaran S, Chey WD, Jackson K, Pillai S, Chey SW. A diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols improves quality of life in patients with irritable bowel syndrome. *Gastroenterology*. 2016; 150(4):899-907.
22. Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. *Am J Gastroenterol*. 2016; 111(11):1517-1527.
23. Varjú P, Farkas N, Hegyi P, Garami A, Szabó I, Illés A, Solymár M, Vincze Á, Balaskó M, Pár G. Low fermentable oligo-, di-, monosaccharides and polyols diet in the treatment of irritable bowel syndrome: A meta-analysis. *Nutrients*. 2017; 9(9):940.
24. O'Keeffe M, Jansen C, Martin L, Williams M, Seamark L, Staudacher HM, Irving PM, Lindsay JO, Whelan K. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms and quality of life in IBS patients. *Nutrients*. 2018; 10(5):610.
25. Whelan K, Martin LD, Staudacher HM, Lomer MCE. The low-FODMAP diet in the management of irritable bowel syndrome: An evidence-based review. *J Hum Nutr Diet*. 2018; 31(2):239-255.
26. Bellini M, Tonarelli S, Barracca F, Rettura F, Pancetti A, Costa F, Marchi S. Low-FODMAP diet: Evidence, doubts and hopes. *Nutrients*. 2020; 12(1):148.
27. Van Lanen AS, de Bree A, Greyling A. Efficacy of a low-FODMAP diet in irritable bowel syndrome: A systematic review. *Nutrients*. 2021; 13(7):2468.
28. Black CJ, Ford AC. Global burden of irritable bowel syndrome and current therapeutic approaches. *Lancet Gastroenterol Hepatol*. 2022; 7(6):545-556.